Similar Levels of Efficacy of Two Different Maintenance Doses of Adalimumab on Clinical Severity and Quality of Life of Patients with Hidradenitis Suppurativa

Similar Levels of Efficacy of Two Different Maintenance Doses of Adalimumab on Clinical Severity and Quality of Life of Patients with Hidradenitis Suppurativa

Adalimumab is the only biologic agent approved for the treatment of moderate-to-severe hidradenitis suppurativa (HS) patients (i.e., with Hurley II or III), which is recommended in two different maintenance doses (i.e., 40 mg weekly or 80 mg every two weeks). We conducted a prospective multicentric...

Full description

Bibliographic Details
Main Authors: Luca Fania, Giulia Giovanardi, Tonia Samela, Dante Caposiena, Andrea Chiricozzi, Flaminia Antonelli, Pierluigi Saraceni, Fulvia Elia, Simone Garcovich, Davide Ciccone, Maria Vittoria Cannizzaro, Emanuele Miraglia, Chiara Iacovino, Sandra Giustini, Nevena Skroza, Alessandra Mambrin, Concetta Potenza, Luca Bianchi, Ketty Peris, Damiano Abeni
Format: Article
Language:English
Published: MDPI AG 2022-07-01
Series:Journal of Clinical Medicine
Subjects:
hidradenitis suppurativa
acne inversa
verneuil disease
adalimumab
patient-reported outcome measures
quality of life
Online Access:https://www.mdpi.com/2077-0383/11/14/4037

Internet

https://www.mdpi.com/2077-0383/11/14/4037

Similar Items